Othman T, Frankel P, Allen P, et al. Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. Haematologica . 2025;110(1):142 ...
Exelixis (EXEL) announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination with atezolizumab in patients with previously ...
NICE is unable to make a recommendation about the use in the NHS of atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in ...
Relevance section written by JCO Associate Editor Gary K. Schwartz, MD, FASCO. The phase Ib COSMIC-021 study evaluated cabozantinib plus atezolizumab in patients with advanced solid tumors. Presented ...
Patients with HCC at high risk of recurrence after resection or local ablation were randomly assigned to receive either atezolizumab plus bevacizumab or active surveillance in the IMbrave 050 study.
In anal cancer, patients receiving pelareorep + atezolizumab continue to show stronger-than-expected responses, outperforming results seen in published studies using checkpoint inhibitors alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback